GlobeNewsWire
13 May 2026, 02:15 UTC · 18w ago
Verdict
Headline takes no side. We score AAPG +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Ascentage Pharma announced that updated results from POLARIS-1, a global registrational Phase 3 study of Olverembatinib in newly diagnosed Ph+ ALL, will be presented at the EHA2026 Congress.
So whatPositive or negative data readouts from global registrational Phase 3 trials are primary catalysts for biotech valuations, directly impacting the asset's commercial and licensing potential.
More positive than 97% of claims this week
The company will present Phase 1b data on the combination of Olverembatinib and Lisaftoclax in pediatric patients with relapsed/refractory Ph+ ALL at the EHA2026 Congress.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
Data on Olverembatinib's efficacy in CP-CML patients with prior resistance to Ponatinib or Asciminib and ASXL1 mutations will be featured at EHA2026.
More positive than 83% of claims this week
Ascentage Pharma will present 17 clinical advances, including 8 poster presentations, for its core assets Olverembatinib and Lisaftoclax at the EHA2026 Congress.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company is presenting 17 clinical advances at a major international congress, indicating strong R&D progress for its core assets.
More positive than 9% of relationship scores this week
[mutual] Ascentage Pharma has entered into global partnerships with AstraZeneca.
More positive than 9% of relationship scores this week
[mutual] Ascentage Pharma has entered into global partnerships with Merck.
More positive than 9% of relationship scores this week
[mutual] Ascentage Pharma has entered into global partnerships with Pfizer.
More positive than 9% of relationship scores this week
[mutual] Ascentage Pharma has entered into global partnerships with Takeda.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
−28.8%
Price is moving against the score
$15.06 vs $21.16 close before publication (May 12) · not market-adjusted
AAPG chart →
